American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. The Ludwig Center at the University of Chicago is searching for new ways to take advantage of cutting-edge technologies to identify, characterize and target disseminated tumor cells, with the goal of eventually developing successful treatment or prevention strategies for metastasis.
WEB: https://www.ludwigcancerresearch.org/location/chicago
Steven J. Chmura. MD, PhD, is a Professor in the Department of Radiation and Cellular Oncology and Director of Clinical and Translational Research at The University of Chicago. He has been actively involved in both the clinical implementation of stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) and related translational and clinical research, as well as the integration of SRS and SBRT into other systemic therapies.
Sean Pitroda, MD, is an Assistant Professor of Radiation and Cellular Oncology at the University of Chicago, and investigates tumor mechanisms that restrict the potential curability of patients with oligometastasis following localized therapies, such as surgery or ablative radiotherapy. His research utilizes integrative genome-wide molecular analyses of clinical metastases, molecular biology, CRISPR-Cas9 genome editing, animal models, immune analysis, and statistical modeling towards translational research goals.
Amy K. Huser is a Technical Writer and Editor who joined the Department of Radiation and Cellular Oncology in 2014. Amy began her career in radiation research last century at the University of Rochester where she worked first with the venerable Phil Rubin, and then his clinical and scientific successors, Paul Okunieff, Jacky Williams, and Jack Finkelstein, focusing on radiation effects in normal tissues and medical countermeasures to radiation terrorism. Amy is a proud graduate of DePaul University and she is happy to have returned to her hometown.
Yang-Xin Fu, MD, PhD, is a Tsinghua University Endowed Professor. Dr. Fu is an internationally renowned cancer immunologist who has pioneered novel immunotherapeutic approaches against cancer including methods to potentiate conventional cancer treatments. His current research interests include investigating and understanding the mechanisms underlying IR-induced extrinsic resistance as well as testing newly developed personalized immunotherapies to overcome the resistance for improved and long-lasting tumor control.
Chuan He, PhD, is the John T. Wilson Distinguished Service Professor in the Department of Chemistry and Department of Biochemistry and Molecular Biology at The University of Chicago. A broad range of investigations are ongoing in the He Lab, including work in the fields of RNA biology, chemical biology, epigenetics, cancer biology, biochemistry, molecular biology, and genomics. Dr. He’s current research focus concerns reversible RNA and DNA methylation in biological regulation.
https://he-group.uchicago.edu
Wenbin Lin, PhD, is the James Franck Professor of Chemistry at The University of Chicago. His group has been exploring materials for application in nonlinear optics, catalysis, uranium sequestration, solar energy, and cancer radiotherapy, chemotherapy, and immunotherapy. The Lin Lab has pioneered the development of two novel classes of molecular nanomaterials—nanoscale metal-organic frameworks (nMOFs) and nanoscale coordination polymers (NCPs)—for the treatment of advanced tumors.
WEB: http://lingroup.uchicago.edu